Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic gets a "positive surprise" from lead asset trial

By: TheNewswire.com

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.31
-0.48 (-0.23%)
AAPL  263.57
-0.78 (-0.30%)
AMD  201.73
+1.61 (0.80%)
BAC  52.65
-0.71 (-1.34%)
GOOG  303.92
-0.02 (-0.01%)
META  643.31
+0.09 (0.01%)
MSFT  401.64
+2.04 (0.51%)
NVDA  187.81
-0.17 (-0.09%)
ORCL  158.27
+2.10 (1.34%)
TSLA  409.64
-1.68 (-0.41%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.